Thermo Fisher Scientific, a leader in scientific services, has unveiled an innovative tool that promises to transform the way clinical trials assess their environmental impact. The newly launched Clinical Trial Carbon Calculator is designed to assist biopharmaceutical companies and research sponsors in measuring and mitigating the ecological footprint associated with clinical research activities. This initiative highlights a significant step towards integrating sustainability into the pharmaceutical industry, which has often overlooked the environmental consequences of clinical trials.
Understanding the Environmental Impact
Clinical trials play a critical role in advancing medical science; however, they can also contribute substantially to greenhouse gas emissions. Research indicates that a single large Phase 3 clinical trial can emit approximately 3,000 metric tons of CO2 equivalent gases, a figure that mirrors the annual carbon footprint of around 176 individuals in the United States. When considering the cumulative emissions from clinical trials worldwide, the impact can be comparable to that of entire countries, such as the British Virgin Islands and the Turks and Caicos.
As stated by Michael J. Cohen, the senior director of environmental sustainability at Thermo Fisher Scientific, the company recognizes its dual obligation of enhancing human health while also safeguarding the planet. The introduction of the Carbon Calculator aims to empower sponsors with the necessary insights to make informed, sustainable decisions during trial design, promoting a proactive approach to environmental responsibility.
Features of the Carbon Calculator
The Carbon Calculator serves as an open access resource that offers a comprehensive framework for evaluating emissions throughout various phases of clinical trials. From the manufacturing of investigational products to patient travel and laboratory processing, the tool quantifies the contribution of each activity to the overall carbon footprint. By doing so, it assists users in pinpointing significant “carbon hotspots,” comparing the carbon efficiency of different study designs, and implementing effective strategies to reduce emissions without sacrificing quality or compliance.
For instance, the adoption of decentralized or hybrid trial models, which incorporate elements like remote monitoring and virtual visits, can lead to notable reductions in travel-related emissions and on-site activities, thereby enhancing the sustainability of clinical trials.
A Collaborative Approach to Sustainability
This initiative is part of a broader commitment by the PPD™ clinical research division of Thermo Fisher Scientific to promote sustainable practices within the clinical development ecosystem. The company aims to collaborate with sponsors, vendors, and investigative sites to embed environmental responsibility into every aspect of study planning and execution. Cohen emphasized that addressing sustainability within clinical development is a collective challenge that requires collaborative solutions. By equipping customers with insights into their carbon emissions, Thermo Fisher Scientific is enabling them to effectuate meaningful changes in their research practices, ensuring that advancements in medicine do not come at the expense of the environment.
For additional information about the Clinical Trial Carbon Calculator, interested parties can visit the official website at carboncalculator.ppd.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is recognized globally as a leader in scientific services, boasting an annual revenue exceeding $40 billion. The organization is dedicated to enabling its customers to achieve healthier, cleaner, and safer outcomes. Whether in the realms of life sciences research, complex analytical challenges, diagnostics, or the development of transformative therapies, Thermo Fisher Scientific remains committed to supporting advancements in scientific innovation. For further details, visit www.thermofisher.com.
Related
